Why the study?
Does the Wistar RA27/3 rubella virus vaccine improve immunologic response and resistance to reinfection compared to other attenuated strains?
Does the Wistar RA27/3 rubella virus vaccine improve immunologic response and resistance to reinfection compared to other attenuated strains?
The RA27/3 rubella vaccine provides superior immunogenicity and resistance to reinfection compared to other attenuated strains, closely mimicking natural infection.
Answers are grounded in this paper and cite their sources.
Supports RA27/3 preference for rubella immunization; leaves open prospective confirmation in modern schedules.
The Wistar RA27/3 strain of rubella virus was attenuated in WI-38 cell culture, and although it induces predominantly subclinical infection, it is immunogenic both intranasally and subcutaneously. The humoral antibody response to this strain administered either way is characterized by hemagglutination-inhibition, complement-fixation, neutralizing, and precipitin antibody responses closer to those of natural rubella than is the case with other attenuated strains. Those who receive live attenuated Wistar RA27/3 rubella virus vaccine develop a resistance to reinfection similar to that following natural infection without the susceptibility to reinfection manifested by those receiving either live attenuated Cendehill or HPV-77 rubella virus vaccines. The induction of nasal antibodies is correlated with this resistance to reinfection with rubella virus. Intranasally administered RA27/3 vaccine, but not subcutaneously administered RA27/3 vaccine, can be used to boost the antibody titer of subjects previously given Cendehill or HPV-77 vaccines.
No takes yet. Share an insight, caveat, or question.
Stanley A. Plotkin (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: